News about Purple Biotech Ltd

Purple Biotech Promising Oncology Developments Amidst Financial Growth
Sep 10 2024
*Abstract:*Purple Biotech Ltd. continues to make strides in the oncology space, specifically with its lead drug candidate, CM24, which is set to be di...

Purple Biotech Advances Oncology Frontiers Positive Pancreatic Cancer Trial Results and New Head and Neck Cancer...
Jul 10 2024
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company based in Rehovot, Israel, is making significant strides in oncolog...

Potential Predictive Biomarker for Improved Overall Survival in Purple Biotechs Pancreatic Cancer Study
Jun 27 2024
Purple Biotech Ltd., a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies, has recently announced additional...

Purple Biotech?s CM24 Shines at ASCO: A Beacon of Hope for Pancreatic Cancer Pa...
Jun 01 2024
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), renowned for pushing the boundaries of cancer treatment, has announced strikingly positive interim results fr...

Unveiling Reduced Risk of Progression or Death in Pancreatic Cancer: Insights from Purple Biotech*s Phase 2 CM24 Study.
Apr 25 2024
In an exciting advancement for pancreatic cancer therapeutics, Purple Biotech has been selected to present a late-breaking abstract poster at the pres...

Purple Biotech Achieves Promising Milestone, Establishes Recommended Phase 2 Dose for Breakthrough Head and Neck Cancer Treatment - NT219
Feb 01 2024
Purple Biotech Advances NT219 in the Treatment of Head and Neck Cancer, Reaching Recommended Phase 2 DoseREHOVOT, Israel, Feb. 01, 2024 - Purple Biote...

Purple Biotech Takes a Bold Leap Forward: $5 Million Offering Paves the Way for Game-Changing Cancer Therapies
Oct 17 2023
Purple Biotech Announces $5 Million Registered Direct Offering: A Boost for Innovative Cancer TherapiesIn an exciting development, Purple Biotech...